Antidral

Quick links to important sections

Antidral

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antidral

Quick Facts

Property Description
Active ingredient Aluminium Chloride Hexahydrate
Form Cutaneous solution (Liquid for skin)
Pharmacological class Antihidrotic / Antiperspirant
Common use Management of excessive sweating (Hyperhidrosis)
Origin Synthetic inorganic salt-based preparation

What Type of Medicine Is Antidral and What Is Its Core Function?

Antidral is clinically recognized as a potent antihidrotic and antiperspirant agent, signifying its role as a specialized pharmaceutical preparation formulated to substantially reduce or prevent the secretion of excessive sweat. Its fundamental therapeutic purpose is the localized management of the symptoms associated with hyperhidrosis, where sweat production exceeds the body's physiological need for cooling. It is marketed as an over-the-counter (OTC) medicine in many regions, emphasizing its accessibility for individuals experiencing problematic levels of wetness.

The solution is an established topical application medication, meaning it is designed to act strictly upon the skin's surface. The use of Aluminium Chloride as a primary agent for severe perspiration is established, recognizing its status as a high-efficacy solution when typical personal care products are insufficient.


Composition and The Astringent Action

The product is a single active ingredient product, relying entirely on Aluminium Chloride Hexahydrate, a synthetic inorganic salt, as its principal therapeutic component. Antidral is presented as a clear cutaneous solution—a liquid preparation for external use. The vehicle for this formulation is an alcoholic and aqueous solution, which includes ethanol and purified water. This base is considered advantageous for promoting quick evaporation and ensuring efficient delivery of the active agent to the sweat ducts, a feature common among pharmaceutical-grade antiperspirants.

Antidral's efficacy is driven by the pronounced astringent properties of the Aluminium Chloride. This mechanism involves the substance chemically reacting with proteins in the superficial layer of the eccrine sweat ducts, causing the tissue to contract. This localized reaction results in the formation of a temporary, functional closure within the duct opening, which physically blocks sweat release. This effect is how the solution directly achieves its antiperspirant outcome.

Regulatory References

  1. Aluminum chloride (DrugBank DB11081)

What side effects are possible with Antidral?

Possible side effects and safety information

The safety profile for Antidral, which contains Aluminium Chloride Hexahydrate, is primarily defined by the occurrence of common local dermatological reactions as documented in official regulatory documents. Adverse reactions are grouped into System-Organ Classes, mainly focusing on Skin and Subcutaneous Tissue Disorders.

Official Adverse Reactions and Frequency

Classification Common Adverse Reactions Serious Adverse Reactions (Rare)
System/Frequency Skin and Subcutaneous Tissue Disorders (Common) Immune System Disorders (Rare)
Examples Local skin irritation, burning sensation, itching (pruritus), and redness (erythema) at the application site. Severe allergic reactions (hypersensitivity), including symptoms of anaphylaxis.

Local symptoms such as mild burning and tingling are often noted as being more common upon initial application at the start of treatment, and these typically resolve with temporary discontinuation of the product. This time-related pattern is an officially recognized characteristic of the medicine's use.

Safety Constraints and Special Populations

Regulatory safety information outlines specific constraints related to systemic exposure. Caution is advised for patients with renal impairment due to the potential for increased systemic exposure to absorbed aluminum, as the kidneys are critical for its clearance. Furthermore, a known hypersensitivity to Aluminium Chloride Hexahydrate or any excipient in the solution is an official contraindication. Safety documentation also classifies the solution as a flammable liquid and emphasizes the potential for severe skin burns or eye damage from improper application or accidental contact, defining the highest tier of potential physical risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Antidral (Aluminium Chloride Hexahydrate topical solution) is defined by the systemic risks associated with accidental ingestion of the liquid. Topical overuse is generally not classified as a severe overdose risk.


Documented Overdose Manifestations

The most serious outcomes are those explicitly documented in regulatory labeling following accidental ingestion:

Element Regulatory Statement Focus
Primary Risk Scenario Accidental Ingestion of the cutaneous solution.
Severe Symptoms Trouble breathing (respiratory distress) or passing out (loss of consciousness).
Allergic Trigger Swelling of the face, lips, tongue, or throat, or chest tightness.
Antidote Information No known specific antidote is detailed in the official prescribing information.

Mandatory Emergency Actions

Government regulatory documents mandate immediate action if accidental ingestion or severe systemic reactions occur:

  • Accidental Ingestion: The explicit instruction is to get medical help or contact a Poison Control Center right away.
  • Urgent Medical Help: Immediate emergency services must be called if the affected individual is exhibiting passing out or severe trouble breathing.

These requirements define the regulator-mandated guidance for handling the severe potential risks linked to this type of exposure.

Therapeutic Uses of Antidral

What Antidral Treats: Main Uses and Benefits

The primary application of Antidral is commonly used for the symptomatic management of hyperhidrosis, which is a condition characterized by perspiration that creates noticeable physiological strain. The solution is applied for the symptomatic management of hyperhidrosis, which is relevant in contexts involving heightened systemic burden involving the axillae, hands, or feet. The solution is indicated for the topical treatment of hyperhidrosis specifically involving localized areas like the armpits, hands, or feet. It is relevant in conditions characterized by periods of heightened symptoms involving these areas of localized perspiration.

Antidral is commonly used to help with symptoms related to conditions presenting with systemic or localized discomfort. It is used for managing symptom clusters that may become intense or disruptive, including symptoms related to heightened physiological activity, associated symptoms that interfere with daily functioning, and symptoms related to inflammatory or irritative states from persistent dampness.

This focused symptomatic support assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations, providing supportive symptom management that may assist with relief in scenarios where additional management of discomfort is required.


Quick Fact: Therapeutic Scope

Property Description
Primary Indication Hyperhidrosis (excessive, problematic sweating)
Symptom Focus Symptoms related to heightened physiological activity, Functional discomfort, Irritative states
Therapeutic Benefit Supports the management of symptoms related to physical discomfort
Relevance Used in conditions characterized by periods of heightened symptoms

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Antidral — Official Regulatory Information

Contraindications and Restrictions

The official regulatory labeling for Antidral (Aluminium Chloride Hexahydrate) establishes clear limits on its use based on anatomical condition and individual health status. The medicine is contraindicated for individuals with known hypersensitivity or allergy to the active substance or any excipient in the formulation.


Eligibility Scope Status Defined by Regulators
Populations for whom use is contraindicated Hypersensitivity to Aluminium Chloride Hexahydrate.
Conditions in which use is prohibited Application to broken, irritated, or recently shaved skin (e.g., within 12 hours).
Condition-specific restricted use Individuals with kidney disease must consult a doctor before use.
Pregnancy and lactation eligibility Conditional use only; requires medical consultation to assess risks and benefits.

Age-Related Eligibility

Antidral is generally indicated for adults and is used in adolescents for the treatment of hyperhidrosis. Use in infants and children is typically subject to special care and caution, often reflecting the greater theoretical risk of systemic aluminum exposure in populations with immature or decreased renal function.

Eligibility-Context Constraints

These constraints define who can and cannot use Antidral: an absolute exclusion is based on ingredient allergy and the condition of the skin, while use is formally restricted for individuals with kidney disease, or for those who are pregnant or breastfeeding.

What should I know about interactions with other medicines?

The efficacy of Antidral (active substance methenamine) is dependent on the conversion of its active substance into its active form, a process that strictly requires an acidic urinary pH (pH 5.5 or lower). Consequently, any medicinal product or substance that raises the urinary pH can substantially reduce or eliminate the drug's effectiveness.

Regulatory documents highlight two primary domains of clinically significant interactions:

Interacting Medicinal Products

Category Specific Examples (Official Labeling) Restriction / Classification
Alkalinizing Agents Antacids (e.g., sodium bicarbonate, calcium carbonate), Carbonic Anhydrase Inhibitors (e.g., acetazolamide) AVOID – Reduces efficacy by preventing conversion.
Sulfonamides Sulfamethizole, Sulfathiazole, Sulfamethoxazole AVOID / Not Recommended – May form insoluble precipitates in the urine.

Procedural and Chemical Basis of Interaction

The most critical restriction is the avoidance of co-administration with any agent that significantly alkalinizes the urine, including specific antacids and certain diuretics. The mechanistic basis for this is a pharmacokinetic alteration; when urinary pH increases, the chemical hydrolysis required to generate the active form of the drug is compromised. This pH-dependent interaction dictates that co-administration with alkalinizing agents is explicitly discouraged or contraindicated due to the high risk of treatment failure.

Mechanism of Action

Antidral functions as an antagonist of the P2Y12 receptor located on the surface of platelets. This primary action selectively modifies the physiological response of the platelet, leading to the inhibition of platelet aggregation. By targeting and modulating this key purinergic signaling pathway, Antidral consequently impacts mechanisms regulating vascular flow. The P2Y12 blockade initiates a specific intracellular cascade: the inhibition of adenylyl cyclase. This inhibition results in a reduction in the concentration of intracellular cyclic AMP ( cAMP), a critical second messenger molecule, within the platelet. The reduction of cAMP levels ultimately contributes to the maintenance of the platelet's resting state, thereby limiting the cellular process of thrombus formation.

Dosage and Administration Information

The use of Antidral (aluminium chloride hexahydrate topical solution) follows a strictly defined, two-phase regimen designed for external cutaneous application.

Official Administration Protocol

Instruction Entity Detail
Route of Administration Topical (Cutaneous application) only. Application is restricted to affected sites: axillae, hands, or feet.
Labeled Dosing Schedule Initial Phase: One application daily at night. Maintenance Phase: After control is achieved (typically after 2 or more treatments), frequency is reduced to once or twice weekly or as needed.
Timing & Duration Must be applied at night (at bedtime) and left on the skin for 6 to 8 hours (overnight). The treated area must be thoroughly washed off the following morning.
Preparation Requirements The skin must be completely dry before application to minimize irritation. The product is highly flammable and must be kept away from flames.
Age-Group Rules Adults, Adolescents, and Older Adults use the standard regimen. Use in children is not established and should be determined by a healthcare provider.
Special Condition When treating the underarms, do not shave or use hair-removal products on the area within 12 hours before or after application.

Summary of Use Protocol

This medicine is applied following a specific, structured course: an initial nightly treatment lasting a few consecutive days, followed by a long-term intermittent pattern dictated by the return of symptoms. The constraints on usage—namely the requirement for completely dry skin, nighttime application, and thorough morning washing—define the procedural conditions necessary for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antidral

Evidence for Use in Managing Armpit Sweating (Axillary Hyperhidrosis)

Research has explored the use of Aluminium Chloride Hexahydrate, the active ingredient in Antidral, in studies examining outcomes related to axillary hyperhidrosis. The evidence landscape primarily consists of small clinical trials, including studies that compared the solution to a placebo. These trials examined outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort, using objective methods like measuring sweat output (gravimetry) and subjective methods like patient questionnaires.

Studies conducted during periods of increased symptom activity report how symptoms evolved in the observed populations. Findings describe patterns observed in the studies related to changes in sweat measurements and how patients reported their experience regarding control of sweating.

Evidence for Use in Managing Sweaty Hands and Feet (Palmar and Plantar Hyperhidrosis)

Studies explored outcomes related to palmar and plantar hyperhidrosis, which are conditions involving periods of heightened symptoms. Research here includes small clinical trials and case series. Studies explored outcomes related to physical discomfort, such as objective measurements of skin water vapor loss, and patient-reported outcomes describing perceived discomfort and activity level. Research also explored scenarios involving the topical solution alongside other localized treatments, such as iontophoresis. Findings in these comparative studies were sometimes mixed.

Duration of Effect and Long-Term Follow-Up Data

Research has primarily examined outcomes describing episodic or acute changes and short-term symptom changes. Data regarding long-term outcomes and the persistence of the studied outcomes are not fully established beyond a year. The high incidence of local irritation observed in some studies was associated with participants dropping out, which limited follow-up durations for some populations.

Strength of the Evidence and Research Limitations

Overall, the research base for topical Aluminium Chloride Hexahydrate was evaluated in numerous studies. The volume of data for axillary hyperhidrosis was evaluated in numerous studies, while the data volume for palmar/plantar hyperhidrosis remains limited. Research is ongoing, but many of the initial studies had modest sample sizes and the follow-up durations were limited. This means that while findings describe group patterns, research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Antidral (FAQ)


Q: Is Antidral the same kind of medicine as other popular drugs for this condition?

Antidral is classified as an anhidrotic, which is a type of antiperspirant medicine that works by physically blocking sweat ducts. Official information indicates that other treatments for excessive sweating may include procedural methods like iontophoresis, or pharmaceutical agents such as topical or oral anticholinergic medicines.

Q: Can I take Antidral if I am also taking vitamins or over-the-counter supplements?

Official regulatory documents advise patients to inform their healthcare provider of all medicines, herbs, non-prescription drugs, and dietary supplements being used. This practice helps ensure compatibility and prevents any unintended interactions that could affect the safety or efficacy of the medicine.

Q: Is it true that Antidral should be taken at the same time every day?

According to official product information, the initial treatment phase is typically applied nightly. However, once control is achieved, the maintenance regimen is often intermittent, requiring application only once or twice weekly or as needed, rather than at a strict daily time.

Q: If I feel better, is it okay to stop Antidral?

The use of this medicine is structured around controlling symptoms. After the initial daily treatments, official guidance states that frequency is reduced to an intermittent, 'as needed' basis, where application is dictated by the return of symptoms.

Q: What does official regulatory information say about the effectiveness of Antidral?

Official information and studies indicate that reduced sweating may be noticed after about two applications of the medicine. Clinical study findings describe that the active ingredient is associated with significant reductions in measured sweat output, which supports its classification as a potent antiperspirant.

Q: What are the general rules for stopping Antidral safely?

Regulatory safety documents state that use should be discontinued immediately if significant skin irritation or an allergic sensitization reaction occurs. Beyond that, the long-term use is not a continuous daily regimen but rather an intermittent application based on when symptoms reappear.

Q: How does Antidral compare to older medicines for the same condition?

Studies and official information indicate this solution is considered a highly effective topical antiperspirant for the management of excessive sweating. It is commonly referenced as an initial topical therapy option when standard antiperspirants are insufficient.

Q: What are the signs that Antidral might not be working for someone?

According to official patient information, a sign that the medicine might not be providing the expected benefit is a failure to notice an improvement in sweating or if the condition appears to worsen. If this occurs, patients are advised to report the development to a healthcare provider.

Q: What are the known potential risks of long-term use of Antidral?

Long-term use is associated with a theoretical risk of cyst formation due to the chronic plugging of the sweat ducts. However, major regulatory agencies generally consider the medicine safe when used as directed, and the evidence regarding links to more serious systemic conditions is inconclusive.

Q: Why are there different dosages available for Antidral?

Different strengths (concentrations) of the solution are available because higher concentrations (e.g., 20% or 30%) are often required for areas with thicker skin, such as the palms and soles. Conversely, lower concentrations may be used in less resistant areas to minimize local skin irritation.

Q: How is Antidral different from non-prescription options?

Specialty antiperspirants, whether they are prescription-only or high-strength over-the-counter options, typically contain a higher concentration of the active ingredient than standard cosmetic antiperspirants. This increased concentration is what provides the higher level of efficacy needed for managing hyperhidrosis.

Q: How quickly should I expect to notice anything after starting Antidral?

Studies and official information indicate that a decrease in sweating may be noticed after about two applications of the medicine. In clinical trials, reduced sweating has been observed within 48 hours following the start of topical application.

Q: Is a headache a normal thing to feel when taking Antidral?

According to official safety information, headache is not listed among the commonly reported side effects of this topical medicine. The most frequently reported adverse reactions are limited to local skin irritation, such as burning or itching, at the application site.

Q: Can Antidral cause stomach issues or digestive problems?

Stomach issues or digestive problems are not typically reported as side effects. This is expected because the medicine is applied topically to the skin, and adverse reactions are primarily confined to local reactions at the application site.

Q: What kind of warnings should I look for regarding Antidral and my liver?

Official regulatory documents emphasize caution and consultation for patients with renal impairment (kidney problems) due to the potential for increased aluminum exposure. Warnings related to the liver are not specifically noted among the contraindications or warnings for this medicine.

Q: Does alcohol interact with Antidral?

While specific systemic interactions between the topical solution and ingested alcohol are not usually detailed, regulatory guidance advises patients to inform their healthcare provider if they drink alcohol.

Q: Can people with high blood pressure use Antidral?

The medicine is intended for topical application to the skin only. Official regulatory warnings do not list cardiovascular conditions like high blood pressure as a contraindication for its use.

Q: What happens if I miss a dose of Antidral?

Official patient information describes that if a dose is missed, the recommended action is to skip the forgotten dose and resume the normal schedule. Applying two doses or extra doses to catch up is generally advised against.

Q: Why do some people report feeling tired when using Antidral?

Tiredness or fatigue is not listed among the adverse reactions in official regulatory safety documents for this topical medicine. The known side effects are almost exclusively local to the skin.

Q: Is Antidral a habit-forming or controlled substance?

This topical solution is not classified as a controlled substance by regulatory bodies. It is also not considered a habit-forming medicine.

Q: Does Antidral affect the ability to drive or operate machinery?

Regulatory information does not list side effects, such as drowsiness or dizziness, that would typically affect a person's ability to drive or operate machinery safely. This is consistent with its topical route of administration.

Q: What happens if a child accidentally takes Antidral?

Official warnings instruct patients that accidental ingestion, particularly by a child, requires immediate medical attention or contact with a Poison Control Center.

Q: Can Antidral cause changes in sleep patterns?

Changes in sleep patterns are not listed among the commonly reported systemic side effects of this medicine. Known side effects are focused on local skin reactions.

Q: Can Antidral make you gain or lose weight?

Weight gain or loss is not listed among the commonly reported systemic side effects of this topical medication.

Q: Does smoking affect how well Antidral works?

Regulatory advice includes informing a healthcare provider if a person smokes. However, specific pharmacokinetic interactions detailing how smoking affects the efficacy of the topical medicine are not noted in official documents.

Q: Does Antidral affect mental focus or mood?

The medicine is not associated with side effects that affect mental focus or mood. This is because adverse reactions are primarily limited to local skin reactions at the application site.

How should Antidral be stored and disposed of?

How to Store and Dispose of Antidral?

Official regulatory information provides specific guidance on the storage and disposal of Antidral (Aluminium Chloride Hexahydrate Cutaneous Solution) to ensure stability and environmental safety.

Storage and Container Requirements

Requirement Description
Environment Store the solution in a cool, dry, and well-ventilated place.
Protection The product must be protected from moisture and kept away from excess heat and incompatible materials.
Container Keep the product in its original container and ensure the cap is tightly closed and sealed after each use.
Child Safety For protection, the medicine must be kept out of the sight and reach of children and stored locked up.

Disposal Instructions

Disposal must adhere to strict environmental guidelines. The solution must not be flushed into surface water, drains, or the sanitary sewer system.

Unused or expired product and its container must be disposed of through an approved waste disposal plant via a licensed waste disposal contractor, in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antidral found in:

A-Z Index: